X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com//news-release/2024/02/22/2833540/0/en/Rhythm-Pharmaceuticals-Announces-Clinical-Development-Plan-of-Setmelanotide-for-Hypothalamic-Obesity-in-Japan.html
https://www.globenewswire.com//news-release/2024/02/07/2825140/0/en/Rhythm-Pharmaceuticals-Announces-Positive-Reimbursement-Decision-in-Italy-for-IMCIVREE-setmelanotide-for-the-Treatment-of-Obesity-and-Control-of-Hunger-in-Bardet-Biedl-Syndrome.html
https://www.globenewswire.com//news-release/2024/01/04/2803812/0/en/Rhythm-Pharmaceuticals-Announces-Completion-of-Screening-for-Enrollment-in-Setmelanotide-Phase-3-Hypothalamic-Obesity-Trial-and-Additional-Updates.html
https://www.globenewswire.com//news-release/2023/11/02/2772213/0/en/Rhythm-Pharmaceuticals-Receives-Positive-CADTH-Reimbursement-Recommendation-for-IMCIVREE-setmelanotide.html
https://www.globenewswire.com//news-release/2023/10/17/2761891/0/en/Rhythm-Pharmaceuticals-Presents-Data-from-its-Long-term-Extension-Study-of-Setmelanotide-Showing-Sustained-and-Deepened-BMI-Reduction-in-Patients-with-Hypothalamic-Obesity-at-One-Y.html
https://www.globenewswire.com//news-release/2023/09/19/2745565/0/en/Rhythm-Pharmaceuticals-Receives-Orphan-Drug-Designation-from-European-Medicines-Agency-for-Setmelanotide-for-Treatment-of-Acquired-Hypothalamic-Obesity.html
https://www.globenewswire.com/news-release/2023/08/07/2719655/0/en/Rhythm-Pharmaceuticals-Announces-Pre-Marketing-Early-Access-Authorization-for-Setmelanotide-for-Use-in-Patients-with-Hypothalamic-Obesity-in-France.html
https://www.clinicaltrialsarena.com/news/imcivree-weight-loss-patients-hypothalamic-obesity/
https://www.globenewswire.com/news-release/2023/05/22/2673311/0/en/Rhythm-Pharmaceuticals-and-Genpharm-Announce-Collaboration-to-Provide-IMCIVREE-setmelanotide-to-Patients-in-Gulf-Cooperation-Council-Countries.html
https://www.globenewswire.com/news-release/2023/05/08/2663261/0/en/Rhythm-Pharmaceuticals-Announces-Health-Canada-Approval-of-IMCIVREE-Setmelanotide-Injection-for-Weight-Management-in-Bardet-Biedl-Syndrome-or-Genetically-confirmed-Biallelic-POMC-P.html
https://www.globenewswire.com/news-release/2023/04/24/2652544/0/en/Rhythm-Pharmaceuticals-Announces-Commercial-Launch-of-IMCIVREE-setmelanotide-in-Germany-for-the-Treatment-of-Obesity-and-Control-of-Hunger-in-Bardet-Biedl-Syndrome.html
https://www.nasdaq.com/press-release/rhythm-pharmaceuticals-announces-vimcivreer-setmelanotide-granted-marketing
https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-vimcivreer-setmelanotide
https://www.globenewswire.com/news-release/2022/11/08/2550733/0/en/Rhythm-Pharmaceuticals-Announces-Publication-of-Results-from-Phase-3-Clinical-Trial-of-IMCIVREE-setmelanotide-in-Bardet-Biedl-Syndrome-in-The-Lancet-Diabetes-and-Endocrinology.html
https://www.globenewswire.com/news-release/2022/10/25/2540781/0/en/Rhythm-Pharmaceuticals-to-Present-Full-Data-from-Phase-2-Clinical-Trial-Evaluating-Setmelanotide-in-Hypothalamic-Obesity-at-ObesityWeek-2022.html
https://www.globenewswire.com/news-release/2022/09/19/2518280/0/en/Rhythm-Pharmaceuticals-Presents-New-Disease-Burden-Findings-and-Analyses-of-Setmelanotide-Data-in-Children-and-Adolescents-with-Rare-MC4R-Pathway-Diseases-at-ESPE-2022.html
https://www.globenewswire.com/news-release/2022/09/06/2510878/0/en/Rhythm-Pharmaceuticals-Announces-IMCIVREE-setmelanotide-Granted-Marketing-Authorization-by-European-Commission-for-Treatment-of-Obesity-and-Control-of-Hunger-in-Bardet-Biedl-Syndro.html
https://www.globenewswire.com/news-release/2022/07/20/2482618/0/en/Rhythm-Pharmaceuticals-Announces-Early-Access-Authorization-for-Setmelanotide-for-Use-in-Patients-with-Bardet-Biedl-Syndrome-in-France.html
https://www.globenewswire.com/news-release/2022/06/22/2467085/0/en/Rhythm-Pharmaceuticals-Launches-IMCIVREE-setmelanotide-in-Germany-for-the-Treatment-of-Obesity-and-Control-of-Hunger-Associated-with-POMC-or-LEPR-Deficiency.html
https://www.biospace.com/article/fda-approves-rhythm-s-drug-for-bardet-biedl-syndrome/
https://www.globenewswire.com/news-release/2022/05/02/2433472/0/en/Rhythm-Pharmaceuticals-Presents-New-Data-from-Phase-3-Trial-Evaluating-Setmelanotide-in-Patients-with-Bardet-Biedl-Syndrome-BBS-at-the-Pediatric-Endocrine-Society-PES-2022-Virtual-.html
https://www.globenewswire.com/news-release/2022/04/06/2417526/0/en/Rhythm-Pharmaceuticals-Optimizes-Design-of-EMANATE-and-DAYBREAK-Clinical-Trials-to-Advance-Setmelanotide-for-Rare-Genetic-Diseases-of-Obesity.html
https://www.globenewswire.com/news-release/2022/02/24/2391401/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Extension-of-Review-Period-for-IMCIVREE-setmelanotide-for-Patients-with-Bardet-Biedl-Syndrome-and-Alstr%C3%B6m-Syndrome.html
https://www.globenewswire.com/news-release/2022/02/16/2386183/0/en/Rhythm-Pharmaceuticals-Announces-Positive-Interim-Data-from-Long-term-Extension-Study-of-Setmelanotide-in-Bardet-Biedl-Syndrome-BBS.html
https://www.globenewswire.com/news-release/2022/01/13/2366546/0/en/Rhythm-Pharmaceuticals-Announces-First-Patients-Dosed-in-DAYBREAK-and-Weekly-Trials-Evaluating-Setmelanotide-for-Rare-Genetic-Diseases-of-Obesity.html
https://www.globenewswire.com/news-release/2021/11/15/2334184/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Acceptance-for-Filing-and-Priority-Review-of-Supplemental-New-Drug-Application-for-IMCIVREE-setmelanotide-for-Patients-with-Bardet-Biedl-Syndro.html
https://www.globenewswire.com/news-release/2021/10/14/2314625/0/en/Rhythm-Pharmaceuticals-Completes-Submission-of-Type-II-Variation-Application-to-the-European-Medicines-Agency-for-IMCIVREE-setmelanotide-for-Bardet-Biedl-and-Alstr%C3%B6m-Syndromes.html
https://www.globenewswire.com/news-release/2021/09/20/2299676/0/en/Rhythm-Pharmaceuticals-Completes-Submission-of-Supplemental-New-Drug-Application-to-U-S-Food-and-Drug-Administration-for-IMCIVREE-setmelanotide-for-the-treatment-of-obesity-and-con.html
https://www.globenewswire.com/news-release/2021/09/08/2293795/0/en/Rhythm-Pharmaceuticals-Announces-Expanded-Access-Program-for-Setmelanotide-for-Patients-with-Bardet-Biedl-Syndrome.html
https://www.ema.europa.eu/en/documents/overview/imcivree-epar-medicine-overview_en.pdf
https://www.sciencedaily.com/releases/2021/04/210415141840.htm#:~:text=in%20the%20brain-,A%203D%20structure%20reveals%20how%20a%20unique%20molecular%20switch%20in,develop%20improved%20anti%2Dobesity%20drugs&text=Summary%3A,or%20MC4%20receptor%20for%20short.
https://www.globenewswire.com/news-release/2021/03/20/2196506/0/en/Rhythm-Pharmaceuticals-Presents-New-Data-from-Phase-2-Basket-Study-Showing-Continued-Weight-Loss-at-Up-to-Nine-Months-in-Patients-with-HET-Obesity-on-Setmelanotide-at-ENDO-2021.html
https://www.globenewswire.com/news-release/2020/11/27/2135269/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Approval-of-IMCIVREE-setmelanotide-as-First-ever-Therapy-for-Chronic-Weight-Management-in-Patients-with-Obesity-Due-to-POMC-PCSK1-or-LEPR-Defic.html
https://globalgenes.org/2020/07/01/fda-grants-rhythm-rare-pediatric-disease-designation-for-rare-obesities-drug/
https://www.globenewswire.com/news-release/2020/06/24/2052662/0/en/Rhythm-Pharmaceuticals-Announces-Positive-Results-from-Phase-2-Study-of-Once-weekly-Formulation-of-Setmelanotide-in-Healthy-Obese-Volunteers.html
https://pink.pharmaintelligence.informa.com/PS142116/EMA-Considers-FastTracking-Rhythms-Insatiable-Hunger--Obesity-Disorders-Drug
https://www.fiercebiotech.com/biotech/as-rhythm-pharmaceuticals-preps-for-first-approval-ceo-hits-exit
https://seekingalpha.com/news/3500676-rhythm-pharma-gets-orphan-status-setmelanotide
Market Place
Share 
